Article Figures & Data
Figures
- FIGURE 1.
Quantification of VEGF expression in tumor cells by ELISA. VEGF levels in cell culture supernatants of 22B (A) and A549 (B) cells were evaluated at 0, 2, 8, and 24 h with or without 1 μM gefitinib treatment (n = 6). **P < 0.01.
- FIGURE 2.
(A and C) In vivo optical imaging of 22B (A) and A549 (C) tumor–bearing mice at 4 h after intravenous injection of 0.5 nmol of Dye-BevF(ab′)2 on days 0, 2, and 5 after initiation of gefitinib treatment (80 mg/kg). (B and D) Quantified 22B (B) and A549 (D) tumor uptake from A and C (n = 5). *P < 0.05. ***P < 0.001.
- FIGURE 3.
VEGF expression in vehicle (control) or gefitinib-treated tumors as determined by immunofluorescence staining and ELISA. (A and C) Immunofluorescence staining of VEGF in 22B (A) and A549 (C) tumor tissues using FITC-bevacizumab (with or without blocking using unlabeled bevacizumab). (B and D) VEGF expression levels in 22B (B) and A549 (D) tumor lysates as determined by ELISA (n = 5). **P < 0.01.
- FIGURE 4.
Antitumorigenic effects of gefitinib treatment. Growth curves of 22B (A) and A549 (B) tumors in nude mice after intraperitoneal administration of 6 doses of gefitinib (80 mg/kg in 50 μL daily) or DMSO (control; 50 μL daily) (n = 5–7). **P < 0.01. ***P < 0.001.
- FIGURE 5.
CD31 and Ki67 staining of vehicle (control) or gefitinib-treated 22B (A) and A549 (B) tumor tissues.
Additional Files
Supplemental Data
Files in this Data Supplement:
